Dashboard

E-Commentary

Go to Commentary

Sponsored
1 year, 10 months ago

Advantages of Services in Eye Physicians

Dr. William Hogue, OD
Directory:
Ophthalmology
Tags:
eye doctor
eye doctor downtown
eye doctor near me
eye doctor nyc
eye physician
eye physician downtown
eye physician near me
eye physician nyc
eye specialist
eye specialist downtown
eye specialist near me
eye specialist nyc
ophthalmologist
ophthalmologist downtown
ophthalmologist manhattan
ophthalmologist nyc
optometrist
optometrist downtown
optometrist manhattan
optometrist near me
optometrist nyc

NYC Eye Physicians are proud to be on USA Newsweek’s list of 350 best ophthalmologists and optometrists. Using the latest advancements and techniques in optometric practices, our doctors offer a full range of Optometry & Ophthalmology services, from eye exams and treatment for dry eyes, burning eyes, and eye stye to an accurate assessment of refractive errors, like nearsightedness/farsightedness/astigmatism, and eyeglasses or contact lenses. At Manhattan Eye Physicians, you’ll find the individualized, compassionate and patient-centric Optometry & Ophthalmology care you need in the safe, reassuring hands of eye experts.

To provide more comprehensive eye care, our optometrists use the newest diagnostic equipment available in the USA, such as Optical Coherence Tomography (OCT), Digital Slit Lamps, Automated Phoropters, Zeiss Visual Field Analyzers, VT1 Vision Screeners and Retina Cameras. These technologies offer earlier detection of various eye-related conditions and improved patient outcomes.

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax: (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

 

 

view in full page
joined 1 year, 10 months ago

Dr. William Hogue, OD

Optometrist
Directory:
Healthcare
Expertise:
Neuro-Ophthalmology
Ophthalmology
Pediatric Ophthalmology

After getting glasses at a young age, Dr. Hogue noticed the startling improvement that vision correction can make. This early experience propelled him to pursue a career where he could make an immediate, positive impact in people’s lives.

Dr. Hogue graduated summa cum laude from the University of Tennessee with a degree in chemistry. He then earned his Doctorate of Optometry (OD) and Master of Science (MS) from New England College of Optometry. Following graduation, he completed a residency in Ocular Disease at the State University of New York’s College of Optometry.

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax:  (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

Find us at: https://care.everydayhealth.com/providers/6489318/william-donald-hogue-od-ms/ 


view this profile
joined 1 year, 10 months ago

Virginia Hearing Consultants

Virginia Hearing Consultants
Directory:
Healthcare
Expertise:
Medical clinic

If you're searching for a trusted medical clinic in Virginia Beach that specializes in audiology, look no further than Virginia Hearing Consultants. Our facility is staffed with experienced audiologists dedicated to improving the hearing health of our community. We understand the impact that hearing issues can have on your quality of life and are equipped to offer comprehensive services tailored to meet individual needs. Our audiology practice is equipped with state-of-the-art diagnostic tools to ensure accurate assessments and treatments for a variety of hearing conditions. As a prominent medical clinic in the area, we pride ourselves on our patient-centered approach, ensuring that everyone who walks through our doors receives attentive care and personalized treatment plans. Whether you need routine hearing evaluations or more complex auditory treatments, Virginia Hearing Consultants is ready to assist you with top-notch audiological care right here in Virginia Beach.

Phone: 757-461-4327


view this profile
1 year, 10 months ago

Henry Wendt, 1933 - 2024

HealthPad
Directory:
Healthcare
Tags:
commentary

Henry Wendt, 1933 - 2024
Obituary

Henry Wendt, born on July 19, 1933, in Neptune City, NJ, passed away on April 11, 2024, leaving behind a legacy that will endure for generations. Raised in Sands Point and Tuxedo Park NY, Henry embarked on a journey after graduating from Princeton University in 1955, starting his career as a salesperson for Smith, Kline & French, an American pharmaceutical company. His dedication and strategic acumen propelled him through various roles within the corporation, spanning locations such as Hawaii, Montreal, Tokyo, and Philadelphia, ultimately culminating in his appointment as President and CEO in 1976.
 
As CEO, Henry implemented a transformative 3-point strategy, reshaping the company's trajectory through strategic divestments and a focus on core products. This foresight laid the groundwork for the historic merger in 1989 with the UK-based Beecham Company, resulting in the formation of SmithKline Beecham (SKB). This was the largest cross-border merger of its time, and heralded the birth of a truly transnational corporation that would redefine global competition in the pharmaceutical industry. Under Henry's leadership, SKB emerged as the world’s second largest pharmaceutical company, both in prescription and over-the-counter drugs, solidifying its position as a global powerhouse.
 
Henry was more than just a businessperson; he was a visionary who recognised the significance of the evolving nature of transnational corporations. In his book, Global Embrace, published in 1993, he described a transition from the era of multinationals to the rise of transnational enterprises, painting a picture of a world where corporate operations transcended national borders in the pursuit of progress and prosperity. Henry's conceptualisation of transnational entities diverged from traditional multinationals primarily in their ownership structure. Unlike their predecessors, transnational corporations boasted a shareholder base that spanned the globe, marking a departure from the conventional reliance on temporary global marketing strategies like foreign branches, offshore acquisitions, joint ventures, or licensing agreements. This distinction emphasised a shift towards a more interconnected and globally oriented business paradigm. Henry's work not only explored market dynamics and competitive strategies but also explored the broader societal implications of this emerging corporate model, advocating for policies that fostered international cooperation and celebrated cultural diversity.

Henry Wendt's influence reached far beyond the boardroom, embodying integrity, moral fortitude, and an unwavering commitment to his country. His life epitomised timeless values of fairness, honesty, and optimism, evident in his many achievements and philanthropic endeavours. His diverse interests mirrored his commitment to improving society, seen through initiatives such as establishing academic chairs, sponsoring educational programmes, and funding research laboratories nationwide. A polymath, Henry found fulfilment in exploration, whether navigating the seas or delving into the realms of knowledge. Through ventures like the Quivira Estate Vineyards and Winery and his contributions to academia and research, his enduring impact continues to inspire future generations. In his passing, Henry Wendt leaves behind a rich legacy of leadership, generosity, and foresight that will echo through the years, serving as a powerful testament to the impact an individual can have on shaping a better world.
  
view in full page
1 year, 10 months ago

A Third Way Growth Strategy for MedTechs

HealthPad
Directory:
Medical Technology
Tags:
commentary
M&A
MedTech
R&D
Startup
  • MedTechs traditionally prioritise M&A over in-house R&D yielding size without always improving quality
  • Amidst healthcare's rapid evolution, companies must explore new avenues for growth and staying competitive
  • Embracing a Third Way, MedTechs can invest in start-ups to access disruptive technologies, mitigate risks, foster growth, and competitive advantage
 
A Third Way Growth Strategy for MedTechs
 
MedTech industry leaders must welcome fresh ideas to maintain their competitive edge and ensure ongoing growth. However, the conventional avenues of development, such as merger and acquisitions (M&A) and in-house research and development (R&D), often encounter obstacles that diminish their effectiveness. As the industry advances, companies face the dual challenge of adopting new technologies while breaking down entrenched organisational barriers. In an era marked by transformative breakthroughs and turbulent market forces, adaptability and innovation are indispensable drivers of success.
 
The line separating established enterprises from agile newcomers has blurred, paving the way for potential collaboration and strategic investment. To excel in this environment, traditional MedTechs should consider recalibrating their conventional growth strategies. Rather than solely relying on M&A or low-risk tweaks to in-house R&D, they should explore a Third Way: investing in and collaborating with a range of innovative start-ups. Giant MedTech have been doing this for decades and reaping the benefits of nascent enterprises, fuelled by high-energy talent, leveraging novel technologies, and offering a fresh approach to growth and value creation.
 
Collaborating with early-stage entities empowers traditional firms to foster a culture of innovation and adaptability, thereby improving patient outcomes and strengthening healthcare systems to thrive in an era of unprecedented change. Effectively managing inventiveness becomes imperative for traditional MedTech companies to successfully navigate the evolving healthcare ecosystem.
 
In this Commentary

This Commentary emphasises the importance for MedTechs to define a clear strategic path in response to the challenges posed by rapid technological advancements, geopolitical shifts, and advancing market dynamics. We propose a Third Way that moves beyond conventional strategies of M&A and internal R&D. We advocate for investment in a varied portfolio of innovative early-stage enterprises focused on developing disruptive healthcare solutions and services. This approach aims to avoid the drawbacks associated with conventional growth strategies and set up MedTechs for long-term growth and improved competitiveness.
 
Challenges of M&A

For more than four decades, the MedTech industry has predominantly relied on M&A as its primary growth strategy, which, over time led to the financialisaton of the industry. Larger conglomerates emerged, but their size does not always translate into enhanced patient outcomes or improved operational efficiency. This pattern emphasises a tendency where short-term financial objectives frequently overshadow longer-term strategies focused on quality systems, organisational structure, and talent within the acquired companies.
In many instances, early-stage enterprises have deficiencies in their operational and human resource systems. These weaknesses are frequently overlooked or insufficiently addressed during the integration phase. While the repercussions of such oversight might not be readily apparent, they tend to surface over time, potentially hindering growth.
You might also like:

The Financialization Dilemma of MedTechs

 
The fallout from prioritising financial integration strategies can jeopardise the long-term viability of the merged entity and hamper its ability to innovate and adapt to shifting market dynamics. Successfully merging disparate corporate cultures, technological platforms, and operational processes requires meticulous planning and execution across all facets of the integration process. Neglecting to allocate adequate time and resources to address these non-financial aspects can lead to disruptions in workflow, employee discontent, and diminished performance.
 
Moving forward, corporations might consider adopting a more balanced approach to growth, one that not only factors in financial gains but also prioritises the assimilation of quality systems, organisational coherence, and human capital to ensure sustained success. Strategic complacency seems to be present in many large entities, and associated with an excessive dependence on conventional M&A for growth can dampen internal innovation.
 
Challenges of In-House R&D

Traditional MedTechs encounter challenges when considering disruptive in-house R&D endeavours. The inherent risks, coupled with resource constraints, often dissuade many traditional companies from pursuing innovative avenues of development. Also, complex regulatory environments present hurdles that require expertise, investment, and stringent compliance measures. The infrastructural needs for integrating new technologies exacerbate the situation, necessitating updates to current manufacturing facilities, supply chains, and distribution networks. These conditions emphasise the demanding nature of pursuing innovative R&D in-house. 

The demands of sales and marketing add additional complexity to internal development initiatives. New offerings require educating healthcare providers and consumers regarding their benefits, alongside developing specialised sales teams and tailored marketing strategies aligned with the product's unique demands. Incentivising sales teams to prioritise new offerings over established ones can be testing, which reinforces the hesitation of traditional MedTechs to pursue disruptive R&D projects.
 
A culture of risk aversion often prevails within traditional firms, leading to a reluctance to depart from established business models and technologies. This is reinforced by corporate structures that highlight stability and predictability over innovation and agility. Executives may hesitate to invest in ground-breaking R&D projects, opting instead for incremental improvements to existing devices. The allure of legacy products, despite their age and slow growth rates, provides a sense of security that dissuades corporations from exploring new technologies.
 
A Third Way

A Third Way for achieving growth and competitiveness, involves investing in innovative early-stage enterprises. Start-up culture thrives on creativity, fuelled by agility, entrepreneurial spirit, and a focus on disruptive solutions. Unlike traditional MedTechs, new ventures are free from the constraints of legacy systems, which enables them to take bold risks and explore new ideas. The collaborative culture of emerging businesses frequently attracts top talent from diverse disciplines, promoting interdisciplinary cooperation and fresh perspectives. This convergence of talent, flexibility, and risk-taking propels start-ups to the forefront of progress, extending the boundaries of what is achievable and contributing to transformative change in healthcare delivery and patient outcomes.
 
Engagement with entrepreneurial businesses warrants larger companies access to cutting-edge technologies while mitigating risk across a portfolio of ventures. Investment in early-stage entities opens avenues for collaboration, partnership, and potential acquisitions, enabling traditional firms to capitalise on emerging trends to maintain and enhance their competitiveness. Overall, embracing a broad-based investment strategy in start-ups represents a prudent approach for traditional MedTechs aiming to reconcile progress with risk.
You might also like:

Healthcare disrupters
Supporting a variety of new ventures that are developing novel products through off-balance sheet investments presents a strategic advantage for traditional corporations. This approach allows them to access advancements without immediately bearing the financial burden of traditional acquisitions, thereby preserving their financial flexibility, and safeguarding their core business. 
By providing tax benefits and mitigating the impact on financial ratios, these commitments contribute to the overall financial wellbeing of the company. Additionally, they facilitate low-risk incremental acquisitions. As start-ups mature and demonstrate success, traditional enterprises can acquire them, leveraging their initial investment and minimising the risk associated with unproven technologies. This model fosters an ecosystem where new entrepreneurial entities thrive with support from established players.
 
Investing in emerging businesses for MedTechs extends beyond financial contributions and can include injections of expertise and knowledge. Established firms possess the capability to offer invaluable guidance and mentorship, drawing on their experience in navigating complex regulations, executing successful clinical trials, and effectively scaling manufacturing operations. By sharing their expertise and knowhow, mature companies amplify the impact of their financial stakes and strengthen their ability and reputation to drive innovation. 
 
The Potential of Venture Arms for MedTechs

The creation of venture arms by leading MedTech companies has facilitated creativity and driven commercial success. Johnson & Johnson (J&J) and Medtronic, for example, have embraced this trend with positive outcomes. J&J's venture initiative, JLabs, was initiated in 2015 in San Francisco to nurture ~50 start-ups across a spectrum of healthcare sectors, including medical devices and digital health. Since then, it has burgeoned into a dynamic ecosystem with key incubation hubs worldwide, from New York to China.
 
While J&J typically refrains from immediate investments, its strategic commitments to enterprises like Mauna Kea Technologies, Protekt Therapeutics, Cara Care, Cala Health, and Sight Diagnostics demonstrate the company's interest in nurturing entrepreneurial solutions aligned with its strategic objectives. Similarly, Medtronic's venture arm has effectively made strategic investments in a diverse array of early-stage businesses, with Axonics as a notable example. Axonics' recent (January 2023) FDA approval for its fourth-generation rechargeable sacral neuromodulation system serves as a testament to the success that can arise from such collaborative endeavours.
 
Traditional MedTech companies can take valuable lessons from industry giants such as J&J and Medtronic, especially in establishing their own venture funds to invest in a range of start-ups. This strategic manoeuvre not only provides these companies access to cutting-edge technologies and disruptive innovations that might outstrip their internal development capacities but also allows them to diversify their product portfolio and helps mitigate risks associated with reliance on a narrow range of offerings.
 
Entrepreneurial ventures often boast agility, enabling them to swiftly bring products to market, surmount bureaucratic hurdles that larger corporations may face, cultivate a culture centred on innovation within their organisations, and inspire employees to explore fresh ideas and collaborate with external partners. However, this can only be achieved if the MedTech market offers realistic opportunities.
 
The MedTech Start-up Market

We have argued that the MedTech start-up market holds potential for traditional companies seeking to revitalise their portfolios to maintain and increase their competitiveness. However, what are the realities of this market? Recent studies shed light on its trends and opportunities, and from these, we can judge whether such investments strategies are a viable option for mature MedTechs.

A 2017 study by the Deloitte Center for Health Solutions and AdvaMed Accel suggested that venture capital investments in early-stage MedTechs were slowing because alongside lacklustre returns, investors showed reluctance towards unproven technologies, and were deterred by regulatory and reimbursement obstacles. However, findings of a similar study repeated in 2021 paint a more promising picture. Since 2017 and the onset of the Covid-19 pandemic in 2020, venture financing in early stage MedTechs surged by ~67%, suggesting a renewed investor confidence. Notably, the bulk of investments were towards late-stage diagnostic and digital companies, highlighting a shift in investor priorities towards more mature ventures. Furthermore, alternative financing avenues such as public markets and family offices have emerged as viable options, opening new pathways for entrepreneurial endeavours. Notwithstanding, amidst this surge, seed, and Series A funding continued to decline, which poses difficulties for fledgling MedTech entities.

For traditional MedTech companies contending with aging legacy products in slow-moving markets, bridging the funding gap presents an opportunity to enhance their growth prospects and strengthen their competitive position. As we have asserted, beyond financial backing, start-ups often seek guidance on regulatory navigation, clinical studies, intellectual property, and reimbursement procedures. Leveraging their wealth of experience and established networks, large firms are ideally situated to provide such valuable insights and support to emerging ventures. 
 
Takeaways

By strategically committing to a diverse range of start-ups, traditional firms bolster their capacity to navigate the complexities of the technology ecosystem. This proactive stance not only positions enterprises to shape the future of healthcare but also augments their prospects for sustained growth and competitiveness in an industry experiencing rapid evolution.
 
Collaborating with emerging businesses at the forefront of technological development empowers large corporations to respond adeptly to market dynamics and drive progress. Such strategic engagement reinforces their relevance in the market, fosters a culture of cooperation and improvement across the healthcare continuum, strengthens traditional enterprises' competitive edge and ensures their long-term viability.
 
The entrepreneurial spirit inherent in start-ups can rejuvenate the development pipelines of traditional MedTechs, enhancing their decision-making and cultivating an environment of creativity conducive to growth. Establishing a fund to invest in start-ups helps to reduce risk and maximise returns, thus protecting corporations against potential disruptions. Adaptation is crucial for survival, and the approach outlined in this Commentary provides traditional companies reliant on legacy offerings with an opportunity to adapt and thrive, reaffirming their relevance in an era characterised by constant change.
view in full page
joined 1 year, 10 months ago

Professional Gynecological Services

Dr. Dmitriy Bronfman, MD
Directory:
Obstetrics and Gynaecology
Expertise:
gyn doctor
gynecology
gynecology clinic
gyn specialist

We Are a Comprehensive Women`s Health Care Facility. The highly skilled and trained professionals at Professional Gynecological Services specialize in providing complete GYN care and New York abortion clinic services in a comfortable, private and supportive environment.

The primary goal of the service is to provide safe healthcare and privacy during stressful times. The purposes are to educate, inform and provide clinical and emotional security. The gynecology center is conveniently located in the heart of Brooklyn with easy access from Manhattan, as well as on Staten Island. Public transportation is accessible, minutes away from the city.

The mission of Professional Gynecological Services is to treat each woman as a whole person, addressing her physical and emotional needs while at our New York Abortion Clinic so that she can make informed health care decisions, provided with safety and discretion. The staff can answer all your questions regarding abortion procedures and information on the abortion pill process (RU486) versus the morning after pill.

Our Services:
Vaginal Rejuvenation
Pelvic Floor Reconstruction
Botox Injections
Permanent birth control (Essure)
Cryosurgery
Gardasil
Colposcopy
Two day abortions (up to 20 weeks)
Dysport Injections
Nexplanon
Hymenotomy
Myomectomy
One day abortions (up to 15 weeks)
Birth control services near me

Prenatal Care Providing High Quality Care In Abortion Services Through 24 Weeks, Specializing in The Abortion Pill Only $350-Ins Ok. Affordable-Safe-Private.

For more information about Professional Gynecological Services or to schedule an appointment, please contact our Brooklyn office by number (718) 875–4848 or our Staten Island office by number (718) 442–3434. Visit the top OB-GYN specialist.

Professional Gynecological Services
14 Dekalb Ave, 2nd Floor,
Brooklyn, NY 11201
(718) 875–4848
Web Address: https://www.thewomenschoice.com/ 

Our location on the map: https://goo.gl/maps/FVeCkjLkTZNiu5c16 

https://plus.codes/87G8M2Q9+W3  Brooklyn

Nearby Locations:
Brooklyn:
Downtown Brooklyn | Clinton Hill | Prospect Heights | Gowanus | Cobble Hill
11201| 11238 | 11217

Working Hours:
Monday: 9 AM — 5:45 PM
Tuesday: 9 AM — 4:45 PM
Wednesday: 9 AM — 5:45 PM
Thursday: 9 AM — 4:45 PM
Friday: 9 AM — 4:45 PM
Saturday: 9 AM — 11:30AM
Sunday: Closed

Payment: cash, check, credit cards.

Our social links:
https://www.facebook.com/TheWomensChoice 

https://twitter.com/TheWomensChoice 

https://www.linkedin.com/company/professional-gynecological-services/ 

https://www.instagram.com/professionalgynservices/ 

https://www.pinterest.com/thewomenschoicenyc

https://www.youtube.com/channel/UCvgN-dbRYbcoEvzfXxo23MA 

https://www.yelp.com/biz/professional-gynecological-services-brooklyn-3

https://www.pinterest.com/thewomenschoicenyc/ 

https://www.tiktok.com/@professionalgynservices 

Find us at: https://www.vitadox.com/practice/brooklyn-ny-11201/professional-gynecological-services/uTzNLaaA2qRJ65wEppsoo9 

View other locations Professional Gynecological Services has been mentioned:
http://www.fsnhospitals.com/profiles/professional-gynecological-services 

https://www.golocal247.com/biz/professional-gynecological-services/brooklyn-ny/LOC10806494 

https://ablocal.com/us/brooklyn-ny/LX1038691-professional-gynecological-services/ 

https://us.centralindex.com/company/1510240536449024 

https://www.vitals.com/doctors/Dr_Dmitriy_Bronfman.html


view this profile
1 year, 10 months ago

Understanding Medical Abortion: Procedures and Risks

Orlando Women's Center
Directory:
Healthcare
Tags:
Medical Abortion
Medical Chemical Abortion
Orlando Women's Center
Understanding Medical Abortion: Procedures and Risks

Women opt for an abortion due to multiple causes. If the gestation is unwanted, there are issues in the growth of the fetus or the life of the mom is in danger because of the pregnancy. The pregnancy can be terminated in two forms. One is by a Surgical Abortion, and the other is by a Medical Abortion.

People prefer medical abortion because of less invasiveness and is possible in the privacy of a home. It is affordable in comparison to traditional surgical abortion. Let us discuss in detail the complete procedure of a medical abortion.

Medical Abortion 

It is also known as an abortion pill but involves taking two medicines needing no surgery or anesthesia.

There are 2 kinds of Medical Abortion.

  1. Methotrexate & Misoprostol
  2. Mifepristone and Misoprostol

 

Methotrexate & Misoprostol (MTX) 


Within the first 49 days of her pregnancy, the patient will take this medication. Oral administration of "Methotrexate" is the first medication. After three to seven days, the second medicine, "Misoprostol," is to be given either orally or vaginally. These medications force the fetus to evacuate itself in hours or days through squeezes and bleeding. In addition, antibiotics are provided to avoid any infections.

Mifepristone and Misoprostol 


Another name for the Abortion Pill approach is RU-486. The patient takes a drug named Mifepristone, which stops Progesterone and stops the pregnancy from growing any further.

The patient then receives a Misoprostol tablet about 36 to 72 hours later. It forms the uterine contractions that lead to the fetus's advanced removal from the body. This procedure can take a few hours or days to complete.

 

Some Adverse Effects 


These are some side effects of the Abortion pill:

  • Infections- Medicinal abortion procedure also has a risk of some infections. So, the doctors prescribe antibiotics along with abortion pills.
  • Cramping and heavy bleeding- The cramping will be painful with a risk of much heavier bleeding. It may need a medical professional's help.
  • Vomiting and diarrhea- The patient can vomit and loose stools as the pills are very strong medications. They have side effects that can be temporary.
  • Nausea- The patients may feel sick and uncomfortable. They might feel dizzy and vomiting.
  • 8 to 10% failure rate- This abortion procedure is effective but still has a failure rate of eight to ten percent. In case of an unsuccessful abortion, a surgical procedure is required for the patient.
  • Non-eligibility- If the patient has ovarian mass, high B.P., or Intrauterine devices, then this abortion procedure may not be advisable due to the health risks involved.
  • Not for patients with chronic diseases- Some patients are suffering previously from chronic diseases like liver, kidney, or bowel disease. Medicinal abortion is not advisable for such patients.
  • Plenty of bed rest- The procedure can sometimes take a toll on the health and overall well-being. It is temporary, and one may need bed rest for a few days to recover.
  • Not suitable for some patients- This medication is not suitable for patients with a history of ectopic pregnancy where the fetus develops outside the uterus and will not grow further.

How can you prepare yourself before a medicinal termination? 


These are some things you can consider before coming to the Abortion Pill Clinic for having an unwanted pregnancy termination.

  1. Knowledge about the procedure
  2. Awareness about the Abortion Legislation in your State
  3. Consideration of finances, affordability, and coverage
  4. Confide in trustworthy people
  5. Arrange for pads, painkillers, water, and food
  6. Bringing along a supporting loved one
  7. Arrangements for things to divert attention
  8. Counseling before and after the procedure
  9. Be confident about your decision
  10. Follow-ups after the procedure


Conclusion 


Medicinal abortion is generally a safe procedure with fewer side effects than many over-the-counter medicines. However, in some patients, the adverse effects might be severe and need immediate medical attention. Orlando Women's Center is an Advanced Abortion Pill Clinic with a supportive staff and a non-judgemental environment. In the case of having a medicinal abortion, you get treatment with compassion and respect in a comfortable environment. Contact us to know more.

 

Orlando Women’s Center
1103 Lucerne Terrace
Orlando, FL 32806
Ph (407) 245-7999
Toll Free (877) 692-2273

Our Location On The Map:  https://www.google.com/maps/place/Orlando+Women's+Center/@28.528912,-81.3805015,17z/data=!3m1!4b1!4m6!3m5!1s0x88e77b0638702803:0xc70c03ccfee1cdd1!8m2!3d28.528912!4d-81.3805015!16s%2Fg%2F1tf5lgnj?entry=ttu

Near By Locations:

Women’s Center Of Hyde Park
4602 N Nebraska Ave,
Tampa, Florida 33606
Ph (813) 258-5995
Toll Free (855) 214-9964


Fort Lauderdale Women’s Center
2161 E Commercial Blvd, Fort Lauderdale, FL 33308
Ph (954) 733-0121
Toll Free (877) 966-3673

 

Working Hours:  24 Hours 7 Days a Week

 

You can also visit our social accounts:

Facebook: https://www.facebook.com/OrlandoWomensCenter

Instagram: https://www.instagram.com/orlandowomenscenter/

 

view in full page
1 year, 10 months ago

Early Surgical Abortion: Procedure, Safety, and Information | Women's Center

Orlando Women's Center
Directory:
Healthcare
Tags:
early surgical abortion
Orlando Women's Center

Learn about early surgical abortion, also known as menstrual extraction, performed at Women's Center. Discover the advancements in medical techniques that allow for the procedure to be performed as early as 3 to 4 weeks into pregnancy. Find out how ultrasound guidance ensures the complete removal of the pregnancy. Understand the process, including cervical preparation, dilation, and the use of a sterile curette. Explore the low complication rate and aftercare instructions. Get comprehensive information and compassionate care at Women's Center for early surgical abortion.

view in full page
joined 1 year, 10 months ago

Genesis Dentistry Dental Group

Genesis Dentistry Dental Group
Directory:
Healthcare
Expertise:
dentistry

Genesis Dentistry Dental Group is a Santa Clara-based dental practice that provides a wide range of dental services including dental implants, Invisalign, veneers, preventive, restorative, and cosmetic dentistry. Our team of highly skilled and experienced dental professionals is committed to providing quality, comprehensive and compassionate care to our patients in a friendly environment. We are conveniently located steps away from the vibrant Santa Clara Farmers Market and the historic University of Santa Clara. If you love a more personalized and advance dental care in a quiet and charming Mission Santa Clara district, then this may be the dental office fit for you.

 

 

Phone Number:
408-260-7384

 

Business Hours:
Monday : Closed
Tuesday : 9:30 am–5:30 pm
Wednesday : 9:30 am–4:30 pm
Thursday : 9:30 am–5:30 pm
Friday : 9:30 am–5:30 pm
Saturday : 9:00 am–3:00 pm
Sunday : Closed

 

Contact mail:
info@genesisdentistrysantaclara.com

 


view this profile
joined 1 year, 10 months ago

Great Teeth Wellington

Great Teeth Wellington
Directory:
Healthcare
Expertise:
dental care

GreatTeeth.co.nz offers dental implants in Wellington that may completely change your smile. Regain functionality and confidence by using our superior services.
With greatteeth.co.nz, get prompt, dependable emergency dental care in Wellington and feel relieved. Count on us to keep your grin intact when things become tough.


view this profile
load more Loading..